Novo Nordisk Adds Mars CEO to Board

Novo Nordisk has elected Poul Weihrauch, the chief executive of Mars, to serve as an observer on its board. This strategic appointment is intended to enhance Novo Nordisk's competitive edge within the U.S. obesity market.

The pharmaceutical company, known for its weight-loss drug Wegovy, also welcomed pharmaceutical industry veterans Jan van de Winkel and Ramona Sequeira to its board, alongside Helena Saxon from H&M. These additions follow a significant leadership restructuring in 2025, which included a CEO change and board reorganization.

Under its new management, Novo Nordisk is actively working to improve its consumer appeal in the United States. Notably, the company launched its Wegovy pill across multiple cash-pay avenues in January, moving beyond traditional insurance routes.

Novo Nordisk is embracing telehealth, retail collaborations, and direct-to-consumer strategies. This approach aligns with the view shared by Novo Nordisk and its rival Eli Lilly and Co that the obesity market is increasingly mirroring consumer-based industries.